GSK (GSK) Share Price, News & Analysis

Company Overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Key Stats

• Today's Range: 1,480.92 to 1,517
• 50-Day Range: 1,311.95 to 1,558.50
• 52-Week Range: 1,282.50 to 1,823.50
• Volume: 7.65 million shs
• Average Volume: 19.17 million shs
• Market Capitalization: £60.26 billion
• P/E Ratio: 23.99
• Dividend Yield: 4.04%
• Price Target: GBX 1,805.83
• Consensus Rating: Moderate Buy

GSK Stock Analysis - MarketRank™

GSK scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GSK has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

GSK has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of GSK is 23.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.53.

Price to Earnings Ratio vs. Sector

The P/E ratio of GSK is 23.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.72.

Price to Earnings Growth Ratio

GSK has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GSK has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GSK.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

GSK is a leading dividend payer. It pays a dividend yield of 4.25%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

GSK does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of GSK is 96.92%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.56

Short Interest

There is no current short interest data available for GSK.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.94

News Sentiment

GSK has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for GSK this week, compared to 5 articles on an average week.

Search Interest

35 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added GSK to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GSK insiders have sold 28,204.48% more of their company's stock than they have bought. Specifically, they have bought £8,120.40 in company stock and sold £2,298,436.71 in company stock.

Percentage Held by Insiders

Only 1.61% of the stock of GSK is held by insiders.

Percentage Held by Institutions

45.33% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GSK Stock Analysis - Frequently Asked Questions

How have GSK shares performed this year?

GSK's stock was trading at GBX 1,346.50 at the beginning of 2025. Since then, GSK stock has increased by 10.3% and is now trading at GBX 1,485.
View the best growth stocks for 2025 here.

How were GSK's earnings last quarter?

GSK plc (LON:GSK) announced its quarterly earnings results on Wednesday, February, 5th. The company reported $23.20 earnings per share for the quarter. GSK had a trailing twelve-month return on equity of 18.08% and a net margin of 8.02%.

How do I buy shares of GSK?

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include AstraZeneca (AZN), Vodafone Group Public (VOD), Lloyds Banking Group (LLOY), Secure Trust Bank (STB), Barclays (BARC), Meta Platforms (META) and Intel (INTC).

Company Calendar

• Ex-Dividend for 1/9 Dividend: 11/14/2024
• Dividend Payable: 1/09/2025
• Last Earnings: 2/05/2025
• Today: 3/24/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:GSK
• CIK: N/A
• Web: www.gsk.com
• Phone: +44-20-80475000
• Fax: N/A
• Employees: 70,212
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 1,805.83
• High Stock Price Target: GBX 2,100
• Low Stock Price Target: GBX 1,600
• Potential Upside/Downside: +21.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 61.91
• Trailing P/E Ratio: 24.05
• Forward P/E Ratio: 8.46
• P/E Growth: 1.24
• Net Income: £2.50 billion
• Net Margins: 8.02%
• Pretax Margin: N/A
• Return on Equity: 18.08%
• Return on Assets: 9.56%

Debt

• Debt-to-Equity Ratio: 114.64
• Current Ratio: 0.81
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: £31.14 billion
• Price / Sales: 1.94
• Cash Flow: GBX 182.80 per share
• Price / Cash Flow: 8.15
• Book Value: GBX 329.73 per share
• Price / Book: 4.52

Miscellaneous

• Outstanding Shares: 4,057,829,779
• Free Float: N/A
• Market Cap: £60.42 billion
• Optionable: Not Optionable
• Beta: 0.31